Picture of Infant Bacterial Therapeutics AB logo

IBT B Infant Bacterial Therapeutics AB Cashflow Statement

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Annual cashflow statement for Infant Bacterial Therapeutics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-47.2-71.9-44.6-65.8-135
Depreciation
Non-Cash Items-5.0414.8-19.3-33.32.07
Other Non-Cash Items
Changes in Working Capital0.127-2.117.412.530.5
Change in Accounts Receivable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities-51.3-58.4-55.6-85.8-101
Financing Cash Flow Items0-0.02-5.03
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Cash from Financing Activities01.760.0911.8896.5
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-47-71.8-36.7-50.9-6.78